Skip to content

A human trial to evaluate the efficacy and safety of steamed Zingiber officinale Roscoe extract powder on joint health

A 12 weeks, randomized, double-blind, placebo-controlled human trial to evaluate the efficacy and safety of steamed Zingiber officinale Roscoe extract powder on joint health

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0006335
Enrollment
100
Registered
2021-07-13
Start date
2021-07-14
Completion date
Unknown
Last updated
2023-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dietary Supplement : • Zingiber officinale Roscoe extract powder group: 1 times a day, 2 tablet once, after breakfast for 12 weeks(1,600 mg/day, 480 mg/day for Zingiber officinale Roscoe extract powd

Sponsors

Woosuk University Korean Medicine Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Participants currently with one or both knees pain 2) Participants with 1~2 of Kellgren Lawrence grade(KL grade) 3) Participants who have fully understand the information provided about the study voluntarily decided to participate and agree to comply with precautions

Exclusion criteria

Exclusion criteria: 1) Patients with a clinically significant disease requiring treatment (i.e., cardiovascular system, endocrine system, immune system, respiratory system, hepatobiliary system, kidney and urinary system, neuropsychiatric system, musculoskeletal inflammation, inflammatory disease, blood and tumor disease, gastrointestinal disease, etc.) 2) Patients who take medicine for joint health and intake health functional food within a month prior to the screening examination 3) Patients with a history of antipsychotic medication use within 3 months prior to the screening examination 4)Patients who have participated in other clinical trials within 3 months prior to the screening examination 5)Patients who are judged ineligible to participate in the trial by the principal investigator for other reasons, including laboratory test outcomes

Design outcomes

Primary

MeasureTime frame
Korean Western Ontario and McMaster Universities Osteoarthritis Index(K-WOMAC) total scores;Visual analog scale(VAS)

Secondary

MeasureTime frame
Korean Western Ontario and McMaster Universities Osteoarthritis Index(K-WOMAC) sub-scores: pain, stiffness, function;Patient global assessment(PGA)

Countries

Korea, Republic of

Contacts

Public ContactSoo jung Park

Woosuk University Korean Medicine Medical Center

taorgi@hanmail.net+82-63-220-8676

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026